Press releases
LIDDS receives NanoZolid® technology patent protection until 2037 LIDDS Delårsrapport april-juni 2018 New STING study opens up multi-billion dollar cancer immunotherapy market for LIDDS unique NanoZolid® technology New legal entity for LIDDS license partner in ChinaCompany Analysis
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Subscribe for news
Press releases
- 2018-09-19 LIDDS receives NanoZolid® technology patent protection until 2037
- 2018-08-30 LIDDS Delårsrapport april-juni 2018
- 2018-07-30 New STING study opens up multi-billion dollar cancer immunotherapy market for LIDDS unique NanoZolid® technology
- 2018-07-09 New legal entity for LIDDS license partner in China
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
